{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:57:53Z","timestamp":1779933473426,"version":"3.53.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T00:00:00Z","timestamp":1449792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Laboratory Medicine"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.plabm.2015.12.004","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T15:55:47Z","timestamp":1450367747000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms"],"prefix":"10.1016","volume":"4","author":[{"given":"Alline","family":"Didone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Nardinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Marchiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Roberto Lancha","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel Lais","family":"de Lima Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael Severino","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia Moreira","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabri Saeed","family":"Sanabani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Bendit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.plabm.2015.12.004_bib1","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"352","volume":"185","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.plabm.2015.12.004_bib2","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.plabm.2015.12.004_bib3","first-page":"937","article-title":"The 2008 Revision of the World Health Organization (WHO) Classification of Myeloid Neoplasms and Acute leukemia: Rationale and Important Changes","volume":"114","author":"Vardiman","year":"2009"},{"key":"10.1016\/j.plabm.2015.12.004_bib4","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMc051878","article-title":"JAK2 mutations in myeloproliferative disorders","volume":"353","author":"Tefferi","year":"2005","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.plabm.2015.12.004_bib5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: a comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.plabm.2015.12.004_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0952-7915(00)00228-4","article-title":"Signaling by type I and II cytokine receptors: ten years after","volume":"13","author":"Gadina","year":"2001","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.plabm.2015.12.004_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation","volume":"14","author":"Lindauer","year":"2001","journal-title":"Protein Eng."},{"key":"10.1016\/j.plabm.2015.12.004_bib8","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.plabm.2015.12.004_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2796.2004.01357.x","article-title":"Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99","volume":"256","author":"Johansson","year":"2004","journal-title":"J. Intern Med."},{"key":"10.1016\/j.plabm.2015.12.004_bib10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.plabm.2015.12.004_bib11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.plabm.2015.12.004_bib12","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.plabm.2015.12.004_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2353\/jmoldx.2009.080110","article-title":"High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms","volume":"11","author":"Rapado","year":"2009","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.plabm.2015.12.004_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.plabm.2015.12.004_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2353\/jmoldx.2006.050130","article-title":"Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis","volume":"8","author":"Lay","year":"2006","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.plabm.2015.12.004_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cca.2009.07.002","article-title":"Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation","volume":"408","author":"Er","year":"2009","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.plabm.2015.12.004_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1373\/clinchem.2005.066068","article-title":"Is the DNA sequence the gold standard in genetic testing? Quality of molecular genetic tests assessed","volume":"52","author":"Bakker","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.plabm.2015.12.004_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm1708","article-title":"with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.plabm.2015.12.004_bib19","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1309\/AJCPFHUQZ9AGUEKA","article-title":"Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods","volume":"132","author":"Cankovic","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.plabm.2015.12.004_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmoldx.2013.07.002","article-title":"Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology","volume":"15","author":"Gong","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.plabm.2015.12.004_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1309\/LW7Q3739RBRMBXXP","article-title":"Comparative evaluation of three JAK2V617F mutation detection methods","volume":"128","author":"Frantz","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.plabm.2015.12.004_bib22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1309\/NXXTGRCXD0TMA3C2","article-title":"Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"125","author":"Greiner","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.plabm.2015.12.004_bib23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.plabm.2015.12.004_bib24","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.plabm.2015.12.004_bib25","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.plabm.2015.12.004_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/sj.leu.2404007","article-title":"Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"20","author":"McClure","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.plabm.2015.12.004_bib27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.5858\/2006-130-997-DOTJMI","article-title":"Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system","volume":"130","author":"Olsen","year":"2006","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.plabm.2015.12.004_bib28","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1309\/1U61JVXTLPPQ7YP1","article-title":"A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation","volume":"127","author":"Tan","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.plabm.2015.12.004_bib29","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.plabm.2015.12.004_bib30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.leu.2404209","article-title":"A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis","volume":"20","author":"Vannucchi","year":"2006","journal-title":"Leukemia"}],"container-title":["Practical Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235255171530007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235255171530007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T12:52:46Z","timestamp":1653828766000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235255171530007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":30,"alternative-id":["S235255171530007X"],"URL":"https:\/\/doi.org\/10.1016\/j.plabm.2015.12.004","relation":{},"ISSN":["2352-5517"],"issn-type":[{"value":"2352-5517","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Practical Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plabm.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}